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Introduction
Optimally managing circulatory shock regularly challenges 
anaesthesiologists tasked with stabilising patients 
for emergency procedures. “Shock” exists when the 
cardiovascular system cannot deliver enough oxygen to 
organs to meet their metabolic needs, resulting in organ 
damage and failure. Disorders of the microcirculation 
(arterioles and capillary beds) are contributors to shock 
states, but therapies to manipulate microcirculation are still 
developing. Therefore, this article focuses on current shock 
management strategies which involve manipulation of the 
heart, arteries and veins, using available agents in South 
Africa.
The circulation can be simplistically modelled as a hydraulic 
system of pipes (the arteries and veins) through which fluid 
(blood) is circulated by a pump (the heart). 
Using this model, shock states can arise from four 
mechanisms:
•	 Too	little	fluid	within	the	system	of	pipes: Hypovolaemic 
shock.
•	 Pump	failure:	Cardiogenic shock.
•	 An	abnormal	 increase	 in	the	size	 (dilation)	of	 the	pipes: 
Distributive shock.
•	 Blockage	 (intravascular	 obstruction	 or	 extravascular	
compression): Obstructive shock.
Therapies must address the shock mechanism or 
combination of mechanisms present in the patient at the 
time. Obstructive shock needs directed therapy to relieve 
the obstruction. Pure hypovolaemic shock, such as that 
from recent haemorrhage, requires only the purposeful 
early replacement of fluid to refill the intravascular volume. 
Management of cardiogenic shock or distributive shock 
necessitates the administration of inotropes or vasopressors, 
respectively, in addition to judicious fluid administration. 
Most shocked patients in anaesthetic practice have multiple 
co-existing shock mechanisms. 
Dysregulated hyperactivation of the innate immune system, 
the systemic inflammatory response syndrome, whether 
driven by infection (“septic shock”) or by tissue injury or 
surgery, simultaneously promotes: 
•	 Absolute hypovolaemia, i.e. fluid leaks from vessels into 
tissues due to endothelium-glycocalyx damage.
•	 Relative hypovolaemia, i.e. blood pools in dilated veins, 
especially splanchnic veins. 
•	 Low arterial pressure due to arteriodilation.
•	 Some cardiac dysfunction, even though cardiac output 
may initially be supranormal.
All of these are aggravated by anaesthetic agents. Thus, 
multimodal therapy is required.
Mechanisms of action of vasopressors 
and inotropes
Calcium (Ca2+) ions are the final regulators of muscle 
contraction in all muscle types, hence all vasoactive 
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agents, except the Ca2+ sensitiser, levosimendan, ultimately 
increase sarcoplasmic Ca2+ concentration in vascular 
smooth muscle or cardiac muscle via the various receptors 
and second messenger pathways described in standard 
texts. Most of the available agents in South Africa are 
adrenoceptor agonists. Excessive intracellular Ca2+ can 
activate the apoptotic pathways.
Appropriate targets
Optimal resuscitation requires goal-directed administration 
of a synergistic balance of fluids, vasopressors and 
inotropes to correct the combination of intravascular volume 
deficit, vasodilation and cardiac dysfunction present in the 
individual patient at that specific time. Adverse effects are 
predictable if the balance is wrong. Side-effects are amplified 
if more of the agent is given than strictly required to achieve 
an adequate life-sustaining circulatory target. Thus, the first 
practical management step is to define haemodynamic 
targets that “should be just enough to sustain life”.
Mean arterial pressure (MAP), the driving pressure for 
blood flow into most organs, is easy to measure and use 
as a target. Based on available (weak) evidence, the adult 
Surviving Sepsis Campaign guidelines recommend that a 
MAP target of 65 mmHg is adequate to perfuse previously 
normal kidneys, and by implication most other organs, 
unless they are in closed compartments with elevated 
compartment pressure when higher MAP targets may be 
justified.1 Using a MAP target is adequate if there is only 
one active mechanism of shock. But since MAP = cardiac 
output x systemic vascular resistance (SVR), and cardiac 
output is itself a result of fluid status (preload), contractility 
and factors that affect myocardial wall tension (afterload) 
using MAP as a sole target may be dangerously misleading 
when several shock mechanisms coexist and abnormalities 
(with divergent effects on MAP) mask each other. Avoiding 
this trap is easier if cardiac output is monitored. Now that 
a range of relatively easy-to-use cardiac output monitoring 
devices is available, an adequate cardiac output will 
become a co-target, alongside an adequate MAP. Cardiac 
output targets are still debated, and probably vary across 
pathologies, but a cardiac index that is any lower than 
2.2 l/minute/m2 is probably inadequate in many patients. 
The debate over the priority of cardiac output versus MAP 
is pointless. Organs such as the kidneys clearly require both 
a good cardiac output and a good MAP.
General considerations
Most vasopressors and inotropes have short half-lives 
(around 45 seconds for adrenaline), and thus require 
continuous regulated infusion, but this gives the benefit 
of titrability. A maximum dose of drugs working via cell 
surface receptors, such as catecholamines (which work via 
adrenoceptors), must exist in each patient and correspond 
to 100% receptor occupancy, beyond which escalation is 
futile. Unfortunately, these maxima vary between patients. 
Co-infusion of agents acting on the same receptors, such 
as adrenaline and phenylephrine, which both stimulate 
alpha1-adrenoceptors, is entirely feasible to allow specific 
titration of cardiac output and SVR, but is only possible 
when each agent is given at “submaximal” doses. Upward 
titration to effect is generally recommended, as many 
agents show hysteresis. The effect of a certain plasma level 
may be different when that plasma level follows a previously 
higher level than when that same level follows escalation 
from a lower level.
Pure inotropes
Dobutamine is a beta 1- and beta 2-cardiac adrenoceptor 
agonist that affords positive inotropy with limited chrono-
tropy. Skeletal muscle arterioles may be dilated by peripheral 
beta 2 effects, hence the “inodilator” label. Thus, dobutamine 
as the sole agent is appropriate for conditions of low 
cardiac output and elevated SVR, such as decompensated 
left ventricular failure and cardiogenic shock, when the 
patient is fluid replete or fluid overloaded. Dobutamine is 
also appropriate, in conjunction with purposeful adequate 
fluid resuscitation and vasopressor use, in the “cold” 
vasoconstricted low cardiac output variant of septic shock.1 
But if given in the presence of uncorrected fluid depletion, 
or of significant vasodilation, the administration of isolated 
dobutamine may precipitate hypotensive collapse. Hence, 
the recommendation is to avoid dobutamine as the initial 
agent in hypotensive patients with vasodilation or fluid 
depletion, until these have been addressed by other agents. 
Titrating dobutamine doses within the recommended range 
up to 20 µg/kg/minute against MAP can be difficult as 
even if cardiac output rises, MAP may decline due to the 
vasodilation. Thus, cardiac output monitoring is essential 
if dobutamine is used in mixed-mechanism shock to 
specifically augment cardiac output. Use of any inotrope in 
patients with cardiogenic shock from myocardial ischaemia 
requires particularly cautious titration to conservative 
cardiac output and MAP targets to avoid worsening of 
ischaemic damage by an excessive increase in myocardial 
workload.
Phosphodiesterase inhibitors, such as milrinone, have 
broadly similar effects to dobutamine, although vasodilation, 
especially pulmonary vasodilation, tends to be more 
prominent, and for licensing reasons, phosphodiesterase 
inhibitors are only available in specialist cardiac centres.
Pure vasopressors
Phenylephrine, an alpha-adrenoceptor agonist, is the 
most commonly used pure vasopressor on the South 
African market as vasopressin is not available, and use 
of ornipressin as a systemic vasopressor is off label. 
Isolated vasopressor usage is logical when the sole active 
shock mechanism is vasodilation and distributive shock. 
Hence, phenylephrine administration constitutes best 
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practice in hypotensive fluid-replete obstetric patients 
after subarachnoid block. Vasopressors given at a low 
dose may constrict abnormally dilated venous beds, 
minimising pooling of blood and improving cardiac preload. 
At a higher dose, they augment arteriolar tension and 
counteract arteriodilation. It might appear logical to add 
phenylephrine to submaximal doses of adrenaline to more 
efficiently reach MAP targets in profoundly vasodilated 
patients with a measured high cardiac output, but otherwise 
phenylephrine is not recommended by the Surviving Sepsis 
Campaign.1 Routinely administering phenylephrine to 
hypotensive anaesthetised patients can be dangerous. 
High doses of phenylephrine can generate high MAPs from 
arterioconstriction, even in critically hypovolaemic patients; 
can critically reduce cardiac output and precipitate cardiac 
failure by imposing an excessive cardiac afterload; and 
can aggravate gut and extremity ischaemia. Many agents 
used in general anaesthesia are negatively inotropic, and 
the inflammatory response to surgery or sepsis may cause 
myocardial dysfunction. Therefore, usage of phenylephrine 
above minimal doses in nonobstetric anaesthesia must 
be accompanied by active correction of fluid deficit and 
diligent cardiac output monitoring.
Multipotent agents
An “all-in-one” drug that combines inotropic and 
vasopressor activity is convenient for most patients with 
multi-mechanism shock, such as those presenting for 
surgery for delayed trauma or sepsis, but with the caveat 
that the inotropy to vasopressor ratio may not be ideal for 
the individual patient and the ratio typically varies as the 
dose is varied. 
The theoretically ideal agent for typical vasodilated septic 
shock, as recommended by the Surviving Sepsis Campaign, 
is noradrenaline (norepinephrine), which has a moderate 
inotropic effect from beta 1-adrenoceptor agonism, coupled 
with effective vasoconstriction due to alpha 1-adrenoceptor 
agonism.1 However, noradrenaline is not available in South 
Africa. 
Dopamine is a time-honoured alternative that stimulates 
both the beta 1- and alpha 1-adrenoceptors, but it has many 
problems that make its ongoing use controversial. It is now 
only recommended by the Surviving Sepsis Campaign in 
restricted circumstances.1 Much of its action is indirect via 
displacement of endogenous noradrenaline from the nerve 
terminals, hence it fails in maximally stressed patients with 
endogenous cathecholamine exhaustion. It suppresses 
thyroid-stimulating hormone release, increases infection 
rates via prolactin suppression, worsens splanchnic 
ischaemia, and any supposed benefit of dopamine 1 
receptor-mediated renal artery dilation is nullified by 
intrarenal shunting. The observed improved urine output 
is owing to a diuretic-like effect. In short, dopamine is not 
renoprotective.2
Adrenaline (epinephrine) is the most commonly used 
mixed vasopressor-inotrope in South Africa. It is potent, 
direct-acting, rapidly titratable, readily available and 
cheap. Titrated within a typical dosing range of 0.05-
1 µg/kg/minute, it is undeniably effective in younger 
patients with sepsis and trauma, but its problems must 
be recognised. It causes excessive tachycardia as it 
stimulates both beta 1- and beta 2-adrenoceptors in the 
heart, which may aggravate myocardial ischaemia and 
increase arrhythmia risk. Beta 2-adrenoceptor-mediated 
peripheral vasodilation offsets some alpha 1-adrenoceptor-
mediated vasoconstriction, hence there is relatively 
inadequate vasoconstriction comparative to inotropy 
for many patients with predominantly distributive shock. 
Adrenaline drives hyperglycaemia and hyperlactataemia. 
While hyperlactataemia is predominantly the consequence 
of adrenaline-accelerated glucose breakdown, and is often 
felt to be benign, it confuses the use of lactate as a marker 
of tissue perfusion adequacy. There are also still concerns 
regarding adrenaline as an aggravator of tissue ischaemia. 
The available studies fail to demonstrate the inferiority of 
adrenaline when it is compared to noradrenaline,3 so it is 
reasonable to say that used with careful monitoring, titrated 
to reasonable MAP and cardiac output goals, in conjunction 
with careful fluid administration, the benefits of adrenaline 
generally outweigh the risks.
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